List of Jornay Pm drug patents
Jornay Pm is owned by Ironshore Pharms.
Jornay Pm contains Methylphenidate Hydrochloride.
Jornay Pm has a total of 15 drug patents out of which 0 drug patents have expired.
Jornay Pm was authorised for market use on 08 August, 2018.
Jornay Pm is available in capsule, extended release;oral dosage forms.
Jornay Pm can be used as method of treating attention deficit hyperactivity disorder (adhd).
The generics of Jornay Pm are possible to be released after 23 March, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9028868 | IRONSHORE PHARMS | Methods and compositions for treatment of attention deficit disorder |
Mar, 2032
(9 years from now) | |
| US9034902 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US8916588 | IRONSHORE PHARMS | Methods for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US9603809 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US10292937 | IRONSHORE PHARMS | Methods of treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US10617651 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US10881618 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US11241391 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US11241392 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US9498447 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US9283214 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US9023389 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US8927010 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US10182995 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
| US10905652 | IRONSHORE PHARMS | Compositions for treatment of attention deficit hyperactivity disorder |
Mar, 2032
(9 years from now) | |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 August, 2018
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic